Ladies and gentlemen, welcome to the Arrowhead Pharmaceutical's Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. I will now hand the conference call over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.

Thank you. Good afternoon, everyone. Thank you for joining us today to discuss Arrowhead's results for its fiscal 2017 third quarter ended June 30, 2017. With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials. Dr. Bruce Given our Chief Operating Officer and head of R&D will also be available during the Q&A portion of the call. Before we begin, I would like to remind you that comments made during today's call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, including without limitation, those with respect to Arrowhead's goals, plans and strategies, are forward-looking statements. These include statements regarding our expectations around the development, safety and efficacy of our drug candidates, projected cash runway and expected future development activities. These statements represent management's current expectations and are inherently uncertain. Thus, actual results may differ materially. Arrowhead disclaims any intent and undertakes no duty to update any of the forward-looking statements discussed on today's call. You should refer to the discussions under risk factors in Arrowhead's annual report on Form 10-K and the Company's subsequent quarterly reports on Form 10-Q for additional matters to be considered in this regard including risks and other considerations that could cause actual results to vary from the presented expected results expressed in today's call. With that said, I would like to turn the call to Christopher Anzalone, President and CEO of the company. Chris?

Thanks, Vince. Good afternoon, everyone, thank you for joining us today. For the last quarter, we had focused on meeting the aggressive timelines we set internally for our development programs while continuing with disciplined cash management. We are excited about our new platforms, our lead drug candidates are progressing rapidly towards the clinic, and our partnership with Amgen continues to be highly productive. These are all important steps for us as a company and give us confidence to push forward with our new and diverse pipeline of RNAi therapeutics. Since we made the decision in November of 2016 to discontinue development of prior generation drugs ARC-520, ARC-521 and ARC-AAT that utilize the EX1 delivery vehicle, we have been quiet about data on our new platform and we grow our candidates that being built upon it. Our plan has been to hold an Analyst R&D Day, to provide comprehensive update about the technology and our lead programs. We think the most effective time to hold this event is when our data across multiple programs have sufficiently matured and when we are in reasonable proximity to file with the regulators to start first in human studies, we are just about there. The Analyst R&D Day is scheduled for Thursday September 14 in New York City. It will be held live so analysts and institutional investors can attend in person and there will also be a webcast so those not in attendance can listen in. That's just 42 days from now so for today's call, I want to talk about the event and what to expect from presentations. There will be two primary components. First, we will discuss our new base platform, then together with expert KOLs we will discuss the three most advanced programs in our pipeline in the clinical and treatment…

Thank you, Chris, and good afternoon everyone. As we reported today our net loss for the three months ended June 30, 2017 was $5.3 million or $0.7 per share based on 74.8 million weighted average shares outstanding. This compares with a net loss of $19.4 million or $0.32 per share based on 60 million weighted average shares outstanding for the three months ended June 30, 2016. Revenue for the three months ended June 30, 2017 was $9.4 million compared to $40,000 for the three months ended June 30, 2016. This increase is driven by the upfront payments we received from our collaboration agreements with Amgen and these payments will continue to be recognized as revenue over the next several quarters. Total operating expenses for the three months ended June 30, 2017 were $14.9 million compared with $19.4 million for the three months ended June 30, 2016. The decrease is driven by the discontinuation of the clinical trials related to our previous clinical candidates. Net cash used by operating activities during the three months ended June 30, 2017 was $10.4 million compared with cash used of $18.3 million during the three months ended June 30, 2016. Cash used in operating activities decreased as compared to last year due to lower spending related to clinical trial expenses. Turning to our balance sheet, our cash in short term investments totaled $75.1 million at June 30, 2017 compared to cash of $85.4 million at September 30, 2016. We've invested $36.8 million in short term corporate bonds that mature within the next 12 months. Our total cash in investment balances decreased $10.2 million as compared to our September 30, 2016 balance. Our cash burn was partially offset by the $30 million upfront payment and a $12.5 million equity investment from Amgen. Our common shares outstanding at June 30, 2017 were 74.8 million. With that, I'll turn the call back to Chris.

Thanks Tim. Thank you all for joining us today and I hope everyone can listen to the presentations at the Analyst R&D Day on September 14. We think our new TRM platform as it is today is the product of many important breakthroughs. It was made possible through years of work and the exploration of countless different technology platforms by talented ARO-AAT scientists who are focused on innovation. We feel that ARO-AAR has always been the high science RNAi company. And we think our presentations at the Analyst Day next month will continue to support that view. We are thrilled to share our progress and we hope that everyone will be as excited about ARO-AAT's future as we are. I would now like to open the call for questions. Operator?

Thank you. [Operator Instructions]. And our first question comes from Madhu Kumar with Chardan. You may proceed.

Hi this is Christine on for Madhu. One question on whether we can expect any clinical or preclinical presentations at the Liver Meeting?

Hi, this is Bruce Given. We will probably do some late breaker submissions. And it's of course always up to be up to the reviewers whether or not they accept those although we've had a pretty good track record of getting them in. So, at this point I can't say for sure, but I wouldn’t be surprised.

[Operator Instructions]. And we have no further questions at the moment. I would now like to turn the call back over to Mr. Chris, you may proceed, sir.

Thanks everyone. I look forward to seeing you and some of you after all at September 14th Analyst Day.

Thank you. Ladies and gentlemen, this does conclude the call. You may all disconnect. Everyone have a great day.